ObjectiveThe aim of the present study was to prospectively evaluate the effect of aclatonium on dry mouth in patients with overactive bladder (OAB) after treatment with solifenacin.MethodsA multicenter randomized double‐blind controlled trial was conducted. The study subjects were men and women who had been diagnosed with OAB for ≥3 months and presented with a total Overactive Bladder Symptom Score (OABSS) ≥3. Eligible subjects were randomized to receive 5 mg solifenacin with placebo or 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks. Subjects rated dry mouth using a visual analog scale (VAS) and completed the OAB‐questionnaire (OAB‐q) short form (SF) and OABSS questionnaires at baseline and after 8 weeks treatment. Dry mouth was defined as a VAS score >30 points (range 0–100).ResultsOverall, 92 patients (49 and 43 in the placebo and aclatonium groups, respectively) completed the 8‐week treatment. In patients who had dry mouth at baseline, no differences were detected in changes in the dry mouth VAS, OABSS, or OAB‐q SF scores between the 2 groups. However, in patients who had no dry mouth at baseline, the change in dry mouth VAS score was significantly lower in the aclatonium‐ than placebo‐treated group: the VAS score increased 20 points in the placebo group compared with 9 points in the aclatonium group (P = .03). However, there were no significant differences in changes in the OABSS and OAB‐q SF scores between the 2 groups.ConclusionsAclatonium decreased dry mouth without disturbing treatment efficacy in patients who did not have dry mouth before treatment.

2003-05-01·Endoscopy1区 · 医学

Food Residue at Endoscopy in Patients Who Have Previously Undergone Distal Gastrectomy: Risk Factors and Patient Preparation

1区 · 医学

Article

作者: Adachi, W ; Yazawa, I ; Watanabe, H ; Koide, N

BACKGROUND AND STUDY AIMSFood residue is often seen in the gastric remnant after partial gastrectomy, making it difficult to diagnose early cancer in the residual stomach. The aims of this study were to clarify the risk factors for the accumulation of food residue, and to study methods of preparation for endoscopy in patients who had undergone distal gastrectomy.PATIENTS AND METHODS374 endoscopic examinations of patients who had undergone distal gastrectomy for gastric cancer were compared with 2168 endoscopic examinations in patients without a history of gastrectomy. Relationships between the presence of food residue and a number of clinical factors, including patient preparation, were evaluated by univariate and multivariate analyses.RESULTSFood residue in the gastric remnant was observed in 70 examinations (18.7 %), a significantly higher proportion than that found in control patients (0.3 %). From multivariate analysis, underlying diseases (endocrine, metabolic, or connective tissue disease), Billroth type I reconstruction, and postoperative gastric retention were found to be independent risk factors for the accumulation of food residue. Diet preparation (a liquid diet plus aclatonium napadisilate) significantly decreased the incidence of food residue.CONCLUSIONSOur diet preparation method can be recommended as a preparation for upper gastrointestinal endoscopy in patients who have undergone distal gastrectomy, especially in patients with additional risk factors.

1990-07-01·Pancreas3区 · 医学

Action of a New Cholinergic Agonist, Aclatonium Napadisilate, on Isolated Rat Pancreatic Acini

3区 · 医学

Article

作者: Masatoshi Fujii ; Satoshi Tani ; Yoshinori Okabayashi ; Takashi Fujisawa ; Makoto Otsuki ; Takahiko Nakamura

The effect of aclatonium napadisilate, a newly synthesized choline ester, on pancreatic exocrine function was compared with that of the muscarinic agonist carbamylcholine in isolated rat pancreatic acini. Both compounds increased amylase release and 45Ca2+ efflux in a dose-dependent fashion, and similarly decreased the binding of [N-methyl-3H]scopolamine to isolated rat pancreatic acini. While aclatonium napadisilate was 20-30 times less potent than carbamylcholine in stimulations of amylase release and 45Ca2+ efflux, the potency of aclatonium napadisilate in inhibiting [N-methyl-3H]scopolamine binding was nearly the same as that of carbamylcholine. These results indicate that aclatonium napadisilate stimulates pancreatic exocrine secretion via muscarinic receptors and Ca2+ mobilization, and its intrinsic activity is less than carbamylcholine in the isolated rat pancreatic acini. Since aclatonium napadisilate is known to increase motility and peristalsis of the gastrointestinal tract, stimulatory effects of aclatonium napadisilate, shown in the present study, on digestive enzyme secretion from the pancreas may provide additional benefit of aclatonium napadisilate in the treatment of various gastrointestinal disorders.

100 项与萘二磺乙乳胆铵相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01955	-	A03FA	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胃肠动力障碍	日本	FUJIFILM Toyama Chemical Co., Ltd.	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胆道运动障碍	临床1期	中国	扬子江药业集团有限公司	2017-12-22
喂食及进食障碍	临床1期	中国	扬子江药业集团有限公司	2017-12-22
胃炎	临床1期	中国	扬子江药业集团有限公司	2017-12-22
恶心	临床1期	中国	扬子江药业集团有限公司	2017-12-22
呕吐	临床1期	中国	扬子江药业集团有限公司	2017-12-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


1960 (AUA2011)	N/A	膀胱过度活动症	92	Solifenacin 5mg	鹽鏇壓簾選鬱積鬱襯襯(築糧築顧淵築鹽廠簾鏇) = 簾憲淵鏇鹹鹽鹹觸憲廠窪淵積鑰鬱窪網蓋糧鬱 (遞遞衊構鬱鬱壓壓網網 )	-	2011-04-01
				Solifenacin 5mg + Aclatonium Napadisilate 150mg	鹽鏇壓簾選鬱積鬱襯襯(築糧築顧淵築鹽廠簾鏇) = 窪鏇艱願網簾築鹹糧衊窪淵積鑰鬱窪網蓋糧鬱 (遞遞衊構鬱鬱壓壓網網 )